Demonstration Formulary
4 Central nervous system
PALLIATIVE CARE PHYSICIANS - Guidelines for the use of drugs in symptom control
04-08-01 Phenobarbital and other barbiturates
| Phenobarbital |
|
Formulary
|
Tablets Elixir On specialist advice MHRA Advice Safety Information Prescriptions for Phenobarbital for children should be prescribed as "unlicensed phenobarbital oral solution 50mg in 5ml (alcohol free)" APC descision September 2021 |
 NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
|
| Primidone |
|
Formulary
|
On specialist advice MHRA Advice |
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
|
|
Links
- Administration of depot antipsychotic injections during COVID-19 in stable adult patients
- ESCA: Eslicarbazepine
- ESCA: Lacosamide
- ESCA: Lacosamide
- ESCA: Lacosamide
- ESCA: Perampanel
- ESCA: Perampanel
- ESCA: Rufinamide
- ESCA: Rufinamide
- ESCA: Vigabatrin
- ESCA: Zonisamide
GlaxoSmithKline: Advance notification of Retigabine (Trobalt) discontinuation- Guidance Document on Valproate Use in Women and Girls of Childbearing Years (March 2019)
- Guidance Document on Valproate Use in Women and Girls of Childbearing Years (March 2019)
- Medicines related to valproate: risk of abnormal pregnancy outcomes
- Medicines related to valproate: risk of abnormal pregnancy outcomes
- MHRA : Valproate use in women and girls (August 2018)
- MHRA safety update on pigmentation July 2013
- MHRA: Letters sent to healthcare professionals in September 2016, including retigabine withdrawal
- MHRA: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) pandemic
- MHRA: Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19) pandemic
- MHRA: Valproate use in women and girls (August 2018)
- MHRA: Valproate use in women and girls (August 2018)
- MHRA: Valproate use in women and girls (August 2018)
- MHRA: Valproate use in women and girls (August 2018)
- NHS England: (Schedule 3 Controlled Drugs) Patient Leaflet; Are you taking gabapentin or pregabalin? (Lyrica, Alzain, Neurontin)
- NHS England: (Schedule 3 Controlled Drugs) Patient Leaflet; Are you taking gabapentin or pregabalin? (Lyrica, Alzain, Neurontin)
- NHS England: (Schedule 3 Controlled Drugs) Patient Leaflet; Are you taking gabapentin or pregabalin? (Lyrica, Alzain, Neurontin)
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137 The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: Epilepsies: diagnosis and management
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
- NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
- NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
- NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
- NICE TA753: Cenobamate for treating focal onset seizures in epilepsy
UKMI Q&A: Anti-depressant use in epileptics: Choice of agent?- UKMI Q&A: Anti-epileptics increasing the risk of osteoporosis?
- UKMI Q&A: Gabapentin and pregabalin - are they safe whilst breast feeding?
- UKMI Q&A: Information on change of phenytoin capsules to tablets and vice versa
- UKMI Q&A: Why is there a limit on the dose and duration of use for carbamazepine suppositories?
- UKMI: The Use of Generic Anti‐Epileptics Drugs in Patients with Epilepsy
- Valproate form: Annual Risk Acknowledgement form (March 2019)
- Valproate form: Annual Risk Acknowledgement form (March 2019)
- Women of childbearing potential: Educational Risk Minimisation Materials
- Women of childbearing potential: Educational Risk Minimisation Materials